CLINICAL TRIALS PROFILE FOR ORKAMBI
✉ Email this page to a colleague
All Clinical Trials for ORKAMBI
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02170025 ↗ | Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients | Terminated | Merck Sharp & Dohme Corp. | Phase 2 | 2014-09-30 | Assessment of the safety, tolerability and early signs of efficacy of three times a day orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients not on treatment with Orkambi |
| NCT02170025 ↗ | Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients | Terminated | Bayer | Phase 2 | 2014-09-30 | Assessment of the safety, tolerability and early signs of efficacy of three times a day orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients not on treatment with Orkambi |
| NCT02589236 ↗ | Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation | Completed | Medidata Solutions | Phase 2 | 2015-11-01 | This will be a double-blind, randomized, placebo-controlled, parallel group study. The purpose of this study is to investigate the efficacy and safety of Cavosonstat (N91115) in adult patients with CF who are homozygous for the F508del-CFTR mutation and being treated with lumacaftor/ivacaftor (Orkambi™). |
| NCT02589236 ↗ | Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation | Completed | Nivalis Therapeutics, Inc. | Phase 2 | 2015-11-01 | This will be a double-blind, randomized, placebo-controlled, parallel group study. The purpose of this study is to investigate the efficacy and safety of Cavosonstat (N91115) in adult patients with CF who are homozygous for the F508del-CFTR mutation and being treated with lumacaftor/ivacaftor (Orkambi™). |
| NCT02653027 ↗ | Effect of Lumacaftor-ivacaftor on Glucose Handling and Tolerance in Cystic Fibrosis Phe508del | Withdrawn | Massachusetts General Hospital | N/A | 2018-01-01 | The purpose of this research study is to find out if the combined therapy lumacaftor-ivacaftor effects how people with cystic fibrosis respond to an oral glucose tolerance test, a test for diabetes. |
| NCT02709109 ↗ | A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation | Completed | Vertex Pharmaceuticals Incorporated | Phase 2 | 2016-02-01 | The purpose of this study is to evaluate the safety and efficacy of treatment with VX-371 in hypertonic saline compared to hypertonic saline alone in subjects with cystic fibrosis (CF) who are ≥12 years of age, homozygous for the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutation, and being treated with Orkambi |
| NCT02709109 ↗ | A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation | Completed | Parion Sciences | Phase 2 | 2016-02-01 | The purpose of this study is to evaluate the safety and efficacy of treatment with VX-371 in hypertonic saline compared to hypertonic saline alone in subjects with cystic fibrosis (CF) who are ≥12 years of age, homozygous for the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutation, and being treated with Orkambi |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ORKAMBI
Condition Name
Clinical Trial Locations for ORKAMBI
Trials by Country
Clinical Trial Progress for ORKAMBI
Clinical Trial Phase
Clinical Trial Sponsors for ORKAMBI
Sponsor Name
